Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase
II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy
for carcinoma of the pancreas. An additional primary objective is to describe the frequency
and nature of grade III/IV and grade I/II toxicities associated with this regimen. Secondary
objectives include describing 1-year disease-free survival and overall survival rates as well
as to estimate clinical and pathologic complete response rates associated with this regimen.